Fortress Biotech 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Stock Price, News & Analysis

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) represents a preferred equity security of Fortress Biotech, Inc., a biopharmaceutical company whose common stock trades under the symbol FBIO on the Nasdaq Capital Market. According to SEC filings, the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock is listed on the Nasdaq Capital Market under the symbol FBIOP, alongside Fortress Biotech’s common stock.

Fortress Biotech, Inc. is described in multiple company press releases as a biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company reports that it has marketed prescription pharmaceutical products and multiple programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries, and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress states that its portfolio is being commercialized and developed for therapeutic areas that include oncology, dermatology and rare diseases.

The FBIOP preferred stock is characterized in SEC filings as 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. The preferred stock is cumulative, meaning unpaid preferred dividends accumulate, and perpetual, meaning the security does not have a scheduled maturity date. The "redeemable" feature is reflected in the name of the series, though specific redemption terms are not detailed in the provided excerpts.

Fortress Biotech’s business model, as described in its news releases, centers on acquiring and advancing biopharmaceutical assets and then generating value from them through product revenue, equity positions and dividend and royalty streams. The company highlights that it has eight marketed prescription pharmaceutical products and that it participates in programs at subsidiaries and partner companies in which it holds majority or significant minority positions. Fortress also notes that it has established partnerships with academic research institutions and biopharmaceutical companies, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital, Columbia University, Dana Farber Cancer Center and Sentynl Therapeutics.

Press releases describe recent regulatory and commercial milestones across Fortress’s broader portfolio, including U.S. Food and Drug Administration approvals for products such as Emrosi and UNLOXCYT (cosibelimab-ipdl), as well as the approval of ZYCUBO (copper histidinate) for Menkes disease through its majority-owned subsidiary Cyprium Therapeutics in collaboration with Sentynl Therapeutics. Fortress also reports monetization events such as the acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharma and the sale of dotinurad-related rights by its subsidiary Urica Therapeutics to Crystalys Therapeutics, with Fortress and its subsidiaries retaining equity positions and royalty rights.

From a capital markets perspective, SEC Form 8-K filings confirm that both Fortress Biotech common stock (FBIO) and the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) are registered securities under Section 12(b) of the Securities Exchange Act of 1934 and trade on the Nasdaq Capital Market. The company is incorporated in Delaware, as indicated in the SEC filings.

Fortress Biotech’s operating focus

In its public communications, Fortress Biotech emphasizes its focus on oncology, dermatology and rare diseases through a network of subsidiaries and partner companies. The company notes that it has eight marketed prescription pharmaceutical products and that it is involved in multiple development programs at different stages. Fortress also points to its use of equity holdings and royalty and dividend income from partner and subsidiary companies as part of its approach to enhancing long-term value.

Recent press releases describe activities at subsidiaries such as Cyprium Therapeutics, which is focused on therapies for Menkes disease and related copper metabolism disorders, and Urica Therapeutics, which is associated with the development of dotinurad for gout through an equity and royalty arrangement with Crystalys Therapeutics. Fortress also reports that Journey Medical Corporation, a partner company, commercializes dermatology products including Emrosi for inflammatory lesions of rosacea in adults.

FBIOP as part of Fortress Biotech’s capital structure

The 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) is reported in Fortress Biotech’s consolidated balance sheets as cumulative redeemable perpetual preferred stock with a stated par value and a designated number of Series A shares. The SEC filings indicate that millions of Series A shares are issued and outstanding and that the series has a liquidation value per share. As a preferred security, FBIOP is structurally distinct from the common stock (FBIO) and appears as a separate class of equity in the company’s capital structure.

Investors reviewing FBIOP typically consider its place within Fortress Biotech’s overall financial position, which is summarized in the company’s periodic financial statements filed with the SEC. The provided balance sheet excerpts show that Fortress reports assets such as cash and cash equivalents, accounts receivable, inventory, intangible assets and other assets, alongside liabilities including notes payable and lease obligations, with stockholders’ equity comprising common stock, additional paid-in capital, accumulated deficit, cumulative redeemable perpetual preferred stock and non-controlling interests.

Relationship between FBIO and FBIOP

Both FBIO and FBIOP are listed on the Nasdaq Capital Market, as disclosed in the SEC Form 8-K filings. FBIO represents the common equity of Fortress Biotech, while FBIOP represents the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. The preferred stock has different characteristics from the common stock, including its stated dividend rate and cumulative, redeemable and perpetual features as reflected in its title. The SEC filings treat the preferred stock as a separate class, and it is identified specifically in the table of securities registered pursuant to Section 12(b) of the Exchange Act.